|
시장보고서
상품코드
2143404
펩타이드 약물 접합체 시장 : 제품별, 종류별, 질환별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)Peptide Drug Conjugates Market, By Product, By Type, By Disease, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033 |
||||||
펩타이드 약물 접합체 시장 규모는 2025년에 52억 8,010만 달러로 평가되며, 2026년부터 2033년까지 CAGR 11.9%로 확대될 것으로 전망됩니다.
펩타이드 약물 접합체(PDC)는 약리학적으로 활성인 약물을 절단 가능하거나 절단 불가능한 링커를 통해 펩타이드 운반체와 결합시키는 표적 치료의 한 형태로 간주됩니다. 펩타이드 약물 접합체의 개념은 표적 펩타이드(표적 세포나 조직 표면에 있는 특정 수용체와 상호작용하는 능력), 전달해야 할 약물 분자, 그리고 약물 분자와 펩타이드 분자를 결합시키는 링커에 기반을 두고 있습니다. PDC는 종양학, 대사성 질환, 희귀질환의 치료에 사용되는 ADC에 비해 수많은 장점을 가지고 있습니다.
펩타이드 약물 접합체 시장 - 시장 역학
암 치료제에 대한 수요 증가가 시장 성장을 가속화
암 치료제에 대한 수요 증가는 펩타이드 약물 접합체의 활용을 촉진하고 있습니다. 이는 표적화된 약물전달, 특이성 향상, 그리고 부작용 감소를 통한 치료 효과 개선으로 암 환자의 의료 서비스 질을 높이기 위함입니다. 예를 들어, 2026년 1월 기준 NIH.gov에 따르면, 2020년 1월부터 2025년 1월까지 EU에서는 종양학 분야에서 60건의 시판 허가 신청(MAA)이 있었으며, 그중 매년 12건이 승인되었습니다. 또한(조사 기간 중) 59건의 신청 건 전부가 긍정적인 평가를 받았으며, 그중 28건(47%)은 혈액암, 10건(17%)은 폐암, 6건(10%)은 유방암이었습니다. 아울러 이 조사에 따르면, 신청 건수의 약 50%가 생명공학 제품이며, 31%가 단일클론 항체인 것으로 밝혀졌습니다. 이러한 동향은 암 치료 및 개발 분야에서 펩타이드 약물 접합체의 채택을 촉진할 것으로 예상됩니다.
펩타이드 약물 접합체 시장 - 시장 세분화 분석:
세계 펩타이드 약물 접합체 시장은 제품 유형, 종류, 질환 및 지역을 기준으로 세분화되어 있습니다.
‘Pluvicto’는 방사성 리간드 요법을 이용하여 진행성 전립선암을 치료하는 약물이므로, 펩타이드 약물 접합체 시장에서 큰 점유율을 차지하고 있습니다. 2025년 3월, 노바티스는 PSMA 양성 전이성 전립선암 치료제인 ‘Pluvicto(루테튬 Lu 177 비피보티드 테트라크세탄)’에 대해 화학요법에 앞서 사용되는 1차 치료제로 미국 FDA로부터 정식 승인을 획득했습니다. 이번 승인으로 적격 환자 수가 증가함에 따라, 해당 약물의 매출액은 3배로 증가할 것으로 전망됩니다. 이러한 적응증 확대로 인해 ‘플루빅토’의 채택이 확대되고, 제조사의 성장이 가속화될 것으로 예상됩니다.
펩타이드 약물 접합체 시장 - 지역별 분석
북미는 암 및 만성 질환의 발생률 증가에 더해 표적 치료의 보급이 확대되고 있어, 펩타이드 약물 접합체 시장에서 두드러진 위치를 차지하고 있습니다. 예를 들어, 2026년 6월 기준 미국 질병통제예방센터(CDC) 보고서에 따르면, 미국의 연령 조정 암 신규 진단률은 인구 10만 명당 453.4건이었습니다. 도시 지역의 경우 10만 명당 450.9건인 반면, 농촌 지역은 10만 명당 466.6건이었습니다. 남성의 경우 10만 명당 490.4건, 여성의 경우 10만 명당 428.9건이었습니다. 이에 따라 해당 지역에서 표적형 펩타이드 기반 암 치료에 대한 수요가 증가할 것으로 보입니다.
유럽의 펩타이드 약물 접합체 시장은 뛰어난 임상 연구 역량과 생명공학 혁신을 촉진하는 정부 정책에 힘입어 성장할 전망입니다. 예를 들어, 2026년 9월 유럽연합 집행위원회(EC)의 CORDIS에 따르면, 생명공학은 유럽연합(EU) 경제에 매년 400억 유로 가까이 기여하고 있으며, 그 중 80% 이상이 의료 생명공학에 의한 것입니다. 또한, 지난 10년간 유럽 생명공학 산업의 성장률은 전체 경제에 비해 2배의 속도로 증가해 왔습니다.
생명공학 분야의 혁신은 유럽 전역에서 ‘호라이즌 유럽(Horizon Europe)’ 이니셔티브를 통해 촉진되고 있으며, 이 프레임워크에서는 의료, 농업, 식품, 에너지, 산업 생산, 화학, 소재, 환경 분야에서의 연구 및 혁신 협력이 추진되고 있습니다. 또한, 유럽집행위원회는 2025년 12월, 지역 내 생명공학 분야의 경쟁력을 강화하기 위해 ‘유럽 생명공학법(European Biotech Act)’ 구상을 제시했습니다. 이러한 노력을 통해 해당 지역 내 펩타이드 약물 접합체의 연구 개발 및 상용화가 촉진될 것으로 기대됩니다.
목차
제1장 펩타이드 약물 접합체 시장 개요
제2장 주요 요약
제3장 펩타이드 약물 접합체 주요 시장 동향
제4장 펩타이드 약물 접합체 산업 분석
제5장 펩타이드 약물 접합체 시장 : 높아지는 지정학적 긴장의 영향
제6장 펩타이드 약물 접합체 시장 구도
제7장 펩타이드 약물 접합체 시장 : 제품별
제8장 펩타이드 약물 접합체 시장 : 유형별
제9장 펩타이드 약물 접합체 시장 : 질환별
제10장 펩타이드 약물 접합체 시장 : 지역별
제11장 주요 벤더 분석 : 펩타이드 약물 접합체 산업
제12장 AnalystView의 전방위 전망
KSM 26.10.14Peptide Drug Conjugates market size was valued at US$ 5,280.1 Million in 2025, expanding at a CAGR of 11.9% from 2026 to 2033.
Peptide Drug Conjugates (PDCs) are considered one of the forms of targeted therapy that involves conjugation of a pharmacologically active drug with a peptide carrier through a cleavable or non-cleavable linker. The concept of peptide drug conjugate is based on the targeting peptide (ability to interact with a specific receptor located on the surface of the target cell or tissue), the drug molecule that should be delivered and linkers coupling the drug and peptide molecules. The PDCs possess a number of advantages over the ADCs that could be used in oncology and metabolic and rare diseases.
Peptide Drug Conjugates Market- Market Dynamics
Rising Demand for Oncology Therapeutics To Accelerate Market Growth
The rising demand for oncology therapeutics is driving the utilisation of peptide drug conjugates because of their targeted drug delivery, improved specificity, and increased therapeutic efficacy through reduced side effects, improving the quality of healthcare for oncology patients. For example, in January 2026, according to NIH.gov, there were 60 oncology Marketing Authorisation Applications (MAAs) in the EU from January 2020 to January 2025, where 12 are being approved each year, and out of the 59 applications (in the study period), 59 had a positive opinion, in which 28 (47%) are blood cancers, 10 (17%) are lung cancers, and 6 (10%) are breast cancers. The study further reveals that around 50% of applications are biotech products, and 31% are monoclonal antibodies. These trends are expected to support peptide drug conjugate adoption in oncology treatment and development.
Peptide Drug Conjugates Market- Segmentation Analysis:
The Global Peptide Drug Conjugates market is segmented on the basis of Product, Type, Disease, and Region.
Pluvicto holds a significant share in the peptide drug conjugate because of the drug as a means for treating advanced cases of prostate cancer using radioligand therapy. In March 2025, Novartis was the quality FDA approval in the US for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), the treatment of PSMA-positive metastatic prostate cancer, as a first-line treatment prior to chemotherapy. This approval will drive up the drug sales threefold due to the number of eligible patients increasing. This expanded approval is expected to increase Pluvicto adoption and support its manufacturers' growth.
Peptide Drug Conjugates Market- Geographical Insights
North America holds a notable position in the Peptide Drug Conjugates market because of the increase in the occurrence of cancer and chronic diseases as well as the increased uptake of targeted treatment. For instance, in June 2026, according to the U.S. Centers for Disease Control and Prevention (Gov), the age-adjusted rate of newly diagnosed cancers in the USA was 453.4 cases per 100,000 people. In urban areas, it was 450.9 per 100,000 people, while in rural regions, it was 466.6 cases of cancer per 100,000 people. Among men, it was 490.4 per 100,000 people, while among women, it was 428.9 cases per 100,000 people. This will propel the demand for targeted peptide-based cancer treatment in the region.
Europe's Peptide Drug Conjugates market will get support due to its high clinical research strength and government policies to encourage innovations in biotechnology. For instance, in September 2026, according to the European Commission's CORDIS, biotechnology adds up to close to EUR 40 billion each year to the European Union economy, where more than 80% comes from health biotechnology. Furthermore, there has been a double growth rate in the biotechnology industry in Europe in the past ten years compared to the economy overall.
The innovation in the biotechnology sector is being encouraged through Europe with the help of its Horizon Europe initiative, wherein collaboration in research and innovation in health, agriculture, food, energy, industrial production, chemistry, materials, and the environment is being promoted. In addition, the European Commission had put forward the concept of the European Biotech Act in December 2025 to enhance the competitiveness of the biotechnology sector within the region. These initiatives are expected to propel peptide drug conjugate research, development, and commercialization in the region.
Peptide Drug Conjugates Market- Competitive Landscape:
Some of the key participants in the Peptide Drug Conjugates market include Bicycle Therapeutics plc, Oncopeptides AB, Theratechnologies Inc., Cybrexa Therapeutics, and Angiochem Inc. The growth in the market is supported by developments in targeted drug delivery, peptide-linker technology, and increasing use of PDCs for the treatment of various diseases, including oncology. In June 2026, Oncopeptides AB started conducting research using OP-701 (INSULA) on patients with glioblastoma, which was the first time when its patented Peptide Drug Conjugate (PDC) platform was subjected to examination in glioblastoma following its success in multiple myeloma. Therefore, advancement in peptide drug conjugate platforms is contributing towards improvements in targeted therapy and oncology.
Recent Developments:
In July 2025, Theratechnologies Inc. announced that the company has signed a definitive agreement to be acquired by CB Biotechnology, LLC, a subsidiary of Future Pak, at a consideration of approximately US$254 million, including contingent value rights, to develop further its portfolio of peptide-drug conjugates (PDC) with su-docetaxel zendusortide (TH1902).
In March 2025, Cybrexa Therapeutics announced new preclinical data for its alphalex(TM) peptide-drug conjugates with tumor-selective targeting and anticancer activity supporting the further development of its pipeline of peptide-drug conjugates (PDC).
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PEPTIDE DRUG CONJUGATES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Novartis AG
- AstraZeneca PLC
- Oncopeptides AB
- Bicycle Therapeutics plc
- Cybrexa Therapeutics, Inc.
- Angiochem Inc.
- Soricimed Biopharma Inc.
- Theratechnologies Inc.
- PeptiDream Inc.
- Curium US LLC
- ProteinQure Inc.
- Protagonist Therapeutics, Inc.
- PepGen Corporation
- Italfarmaco S.p.A.
- Zealand Pharma A/S
- BioNTech SE
- Others
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033
- OctreoScan
- Lutathera
- Pluvicto
- Illuccix
- Others
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033
- Therapeutic
- Diagnostic
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033
- Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Multiple Myeloma
- Others
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Table of Contents
1. Peptide Drug Conjugates Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Peptide Drug Conjugates Market Snippet by Product
- 2.1.2. Peptide Drug Conjugates Market Snippet by Type
- 2.1.3. Peptide Drug Conjugates Market Snippet by Disease
- 2.1.4. Peptide Drug Conjugates Market Snippet by Country
- 2.1.5. Peptide Drug Conjugates Market Snippet by Region
- 2.2. Competitive Insights
3. Peptide Drug Conjugates Key Market Trends
- 3.1. Peptide Drug Conjugates Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Peptide Drug Conjugates Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Peptide Drug Conjugates Market Opportunities
- 3.4. Peptide Drug Conjugates Market Future Trends
4. Peptide Drug Conjugates Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Peptide Drug Conjugates Market : Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Peptide Drug Conjugates Market Landscape
- 6.1. Peptide Drug Conjugates Market Share Analysis, 2025
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Peptide Drug Conjugates Market - By Product
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
- 7.1.2. OctreoScan
- 7.1.3. Lutathera
- 7.1.4. Pluvicto
- 7.1.5. Illuccix
- 7.1.6. Others
8. Peptide Drug Conjugates Market - By Type
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
- 8.1.2. Therapeutic
- 8.1.3. Diagnostic
9. Peptide Drug Conjugates Market - By Disease
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Disease, 2025 & 2033 (%)
- 9.1.2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- 9.1.3. Multiple Myeloma
- 9.1.4. Others
10. Peptide Drug Conjugates Market - By Geography
- 10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
- 10.2. North America
- 10.2.1. Overview
- 10.2.2. Peptide Drug Conjugates Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.2.7. U.S.
- 10.2.7.1. Overview
- 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.2.7.3. U.S. Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.2.7.4. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.2.7.5. U.S. Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.2.8. Canada
- 10.2.8.1. Overview
- 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.2.8.3. Canada Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.2.8.4. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.2.8.5. Canada Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3. Europe
- 10.3.1. Overview
- 10.3.2. Peptide Drug Conjugates Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.7. Germany
- 10.3.7.1. Overview
- 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.7.3. Germany Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.7.4. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.7.5. Germany Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.8. UK
- 10.3.8.1. Overview
- 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.8.3. UK Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.8.4. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.8.5. UK Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.9. France
- 10.3.9.1. Overview
- 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.9.3. France Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.9.4. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.9.5. France Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.10. Italy
- 10.3.10.1. Overview
- 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.10.3. Italy Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.10.4. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.10.5. Italy Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.11. Spain
- 10.3.11.1. Overview
- 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.11.3. Spain Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.11.4. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.11.5. Spain Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.12. The Netherlands
- 10.3.12.1. Overview
- 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.12.3. The Netherlands Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.12.4. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.12.5. The Netherlands Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.13. Sweden
- 10.3.13.1. Overview
- 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.13.3. Sweden Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.13.4. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.13.5. Sweden Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.14. Russia
- 10.3.14.1. Overview
- 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.14.3. Russia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.14.4. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.14.5. Russia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.15. Poland
- 10.3.15.1. Overview
- 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.15.3. Poland Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.15.4. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.15.5. Poland Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.16. Denmark
- 10.3.16.1. Overview
- 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.16.3. Denmark Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.16.4. Denmark Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.16.5. Denmark Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.3.17. Rest of Europe
- 10.3.17.1. Overview
- 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.3.17.3. Rest of the Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.3.17.5. Rest of the Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Peptide Drug Conjugates Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.7. China
- 10.4.7.1. Overview
- 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.7.3. China Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.7.4. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.7.5. China Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.8. India
- 10.4.8.1. Overview
- 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.8.3. India Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.8.4. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.8.5. India Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.9. Japan
- 10.4.9.1. Overview
- 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.9.3. Japan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.9.4. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.9.5. Japan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.10. South Korea
- 10.4.10.1. Overview
- 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.10.3. South Korea Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.10.4. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.10.5. South Korea Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.11. Australia
- 10.4.11.1. Overview
- 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.11.3. Australia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.11.4. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.11.5. Australia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.12. Indonesia
- 10.4.12.1. Overview
- 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.12.3. Indonesia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.12.4. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.12.5. Indonesia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.13. Thailand
- 10.4.13.1. Overview
- 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.13.3. Thailand Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.13.4. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.13.5. Thailand Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.14. Philippines
- 10.4.14.1. Overview
- 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.14.3. Philippines Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.14.4. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.14.5. Philippines Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.15. Taiwan
- 10.4.15.1. Overview
- 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.15.3. Taiwan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.15.4. Taiwan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.15.5. Taiwan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.16. Vietnam
- 10.4.16.1. Overview
- 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.16.3. Vietnam Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.16.4. Vietnam Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.16.5. Vietnam Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.4.17. Rest of APAC
- 10.4.17.1. Overview
- 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.4.17.3. Rest of APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.4.17.4. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.4.17.5. Rest of APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Peptide Drug Conjugates Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.7. Brazil
- 10.5.7.1. Overview
- 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.7.3. Brazil Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.7.4. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.7.5. Brazil Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.8. Mexico
- 10.5.8.1. Overview
- 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.8.3. Mexico Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.8.4. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.8.5. Mexico Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.9. Argentina
- 10.5.9.1. Overview
- 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.9.3. Argentina Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.9.4. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.9.5. Argentina Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.10. Colombia
- 10.5.10.1. Overview
- 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.10.3. Colombia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.10.4. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.10.5. Colombia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.5.11. Rest of LATAM
- 10.5.11.1. Overview
- 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.5.11.5. Rest of LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Peptide Drug Conjugates Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.7. Saudi Arabia
- 10.6.7.1. Overview
- 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.7.5. Saudi Arabia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.8. UAE
- 10.6.8.1. Overview
- 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.8.3. UAE Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.8.4. UAE Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.8.5. UAE Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.9. Israel
- 10.6.9.1. Overview
- 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.9.3. Israel Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.9.4. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.9.5. Israel Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.10. Turkey
- 10.6.10.1. Overview
- 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.10.3. Turkey Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.10.4. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.10.5. Turkey Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.11. Algeria
- 10.6.11.1. Overview
- 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.11.3. Algeria Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.11.4. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.11.5. Algeria Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.12. Egypt
- 10.6.12.1. Overview
- 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.12.3. Egypt Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.12.4. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.12.5. Egypt Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.13. Iran
- 10.6.13.1. Overview
- 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.13.3. Iran Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.13.4. Iran Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.13.5. Iran Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.14. Qatar
- 10.6.14.1. Overview
- 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.14.3. Qatar Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.14.4. Qatar Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.14.5. Qatar Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
- 10.6.15. Rest of MEA
- 10.6.15.1. Overview
- 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 10.6.15.3. Rest of MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 10.6.15.4. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 10.6.15.5. Rest of MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11. Key Vendor Analysis- Peptide Drug Conjugates Industry
- 11.1. Competitive Benchmarking
- 11.1.1. Competitive Dashboard
- 11.1.2. Competitive Positioning
- 11.2. Company Profiles
- 11.2.1. Novartis AG
- 11.2.2. AstraZeneca PLC
- 11.2.3. Oncopeptides AB
- 11.2.4. Bicycle Therapeutics plc
- 11.2.5. Cybrexa Therapeutics, Inc.
- 11.2.6. Angiochem Inc.
- 11.2.7. Soricimed Biopharma Inc.
- 11.2.8. Theratechnologies Inc.
- 11.2.9. PeptiDream Inc.
- 11.2.10. Curium US LLC
- 11.2.11. ProteinQure Inc.
- 11.2.12. Protagonist Therapeutics, Inc.
- 11.2.13. PepGen Corporation
- 11.2.14. Italfarmaco S.p.A.
- 11.2.15. Zealand Pharma A/S
- 11.2.16. BioNTech SE
- 11.2.17. Others
12. 360 Degree AnalystView
13. Appendix
- 13.1. Research Methodology
- 13.2. References
- 13.3. Abbreviations
- 13.4. Disclaimer
- 13.5. Contact Us
